Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

References

• Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4(3):965–994.
   PubMed Web of Science ®Google Scholar
• Capelli I, Gasperoni L, Ruggeri M, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol. 2020 Feb;33(1):37–48.
   PubMed Web of Science ®Google Scholar
• Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257–263.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Jaisser F, Kim SY, et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305.
   PubMedGoogle Scholar
• Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42(3):293–300.
   PubMed Web of Science ®Google Scholar
• Schwenk MH, Hirsch JS, Bomback AS. Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis. 2015;22(2):123–132.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Zannad F, Jj M, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001;19(3):185–200.
   PubMedGoogle Scholar
• Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008 Apr;31(4):153–158.
   PubMed Web of Science ®Google Scholar
• Vukadinović D, Lavall D, Vukadinović AN, et al. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017 Jun;188:99–108.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan;7(1):51–58.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Heart Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020 Aug;22(8):1378–1389.
   PubMed Web of Science ®Google Scholar
• Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018 Aug;20(8):1217–1226.
   PubMed Web of Science ®Google Scholar
• Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303.
   PubMed Web of Science ®Google Scholar
• Alexandrou ME, Papagianni A, Tsapas A, et al. Bakris G and Sarafidis P. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(12):2307–2324.
   PubMed Web of Science ®Google Scholar
• Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217(1–2):27–31.
   PubMed Web of Science ®Google Scholar
• Bamberg K, Johansson U, Edman K, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One. 2018;13(2):e0193380.
   PubMed Web of Science ®Google Scholar
• Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932–29940.
   PubMed Web of Science ®Google Scholar
• Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226–234.
   PubMed Web of Science ®Google Scholar
• Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385–1403.
   PubMed Web of Science ®Google Scholar
• Chow CP, Liu JR, Tan XJ, et al. Pharmacological Profile of KBP-5074, a novel nonsteroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases. J Drug Res Dev. 2017;3(2): doi https://doi.org/10.16966/2470-1009.137.
   Google Scholar
• Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350(2):310–317.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ubukata O, Homma T, et al. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS Lett. 2020 May;594(10):1615–1623.
   PubMed Web of Science ®Google Scholar
• Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266–773.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014 Jul;64(1):69–78.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kawaguchi A. Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Apr;10(4):353–365.
   PubMed Web of Science ®Google Scholar
• Granberg KL, Yuan ZQ, Lindmark B, et al. Identification of mineralocorticoid receptor modulators with low impact on electrolyte homeostasis but maintained organ protection. J Med Chem. 2019;62(3):1385–1406.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012 Jun;14(6):668–675.
   PubMed Web of Science ®Google Scholar
• Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876–21889.
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985 Oct;38(4):469–474.
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact. 1987;5(4):273–302
   PubMedGoogle Scholar
• Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003 Nov;31(11):1448–1455.
   PubMed Web of Science ®Google Scholar
• Erlandsson F, Albayaty M, Chialda L, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. Br J Clin Pharmacol. 2018;84(7):1486–1493.
   PubMed Web of Science ®Google Scholar
• Whittaker A, Åm K, Hartleib-Geschwindner J, et al. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: a Phase I Multiple Ascending Dose Study. Clin Transl Sci. 2020 Mar;13(2):275–283.
   PubMed Web of Science ®Google Scholar
• Kato M, Furuie H, Shimizu T, et al. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018 Aug;84(8):1821–1829.
   PubMed Web of Science ®Google Scholar
• Yamada M, Mendell J, Takakusa H, et al. Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans. Drug Metab Dispos. 2019 Mar;47(3):340–349.
   PubMed Web of Science ®Google Scholar
• Ito S, Itoh H, Rakugi H, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33(7):542–551.
   PubMed Web of Science ®Google Scholar
• Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): phase 3 Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715–1727.
   PubMed Web of Science ®Google Scholar
• Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, et al. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016 Apr;30(2):172–184.
   PubMed Web of Science ®Google Scholar
• Gerisch M, Heinig R, Engelen A, et al. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018 Nov;46(11):1546–1555.
   PubMed Web of Science ®Google Scholar
• Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, et al. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. Clin Pharmacol Drug Dev. 2016 Nov;5(6):488–501.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019 Oct 26;394(10208):1540–1550.
   PubMed Web of Science ®Google Scholar
• Snelder N, Heinig R, Drenth HJ, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase iib data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020 Mar;59(3):359–370.
   PubMed Web of Science ®Google Scholar
• Ito S, Itoh H, and Rakugi H, et al. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021 44 (5): 489–497. Dec 16.
   PubMed Web of Science ®Google Scholar
• Ito S, Shikata K, Nangaku M, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1161–1172.
   PubMed Web of Science ®Google Scholar
• Sattar Bhuiyan A, Rafiq K, Kobara H, et al. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42(6):892–902.
   PubMed Web of Science ®Google Scholar
• Bamberg K, William-Olsson L, Johansson U, et al. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. J Renin Angiotensin Aldosterone Syst. 2019;20(1):1470320319827449.
   Web of Science ®Google Scholar
• Jaisser F, Tan X, Chi S, et al. The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury. Front Pharmacol. 2021 Jun 24;12:604928.
   PubMed Web of Science ®Google Scholar
• Grune J, Benz V, Brix S, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402–411.
   PubMed Web of Science ®Google Scholar
• Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension 2018;71(4):599–608.
   PubMed Web of Science ®Google Scholar
• Marzolla V, Feraco A, Limana F, et al. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J. Endocrinol Invest. 2021 Jul;16:1–6.
   Google Scholar
• Ruhs S, Nolze A, Hübschmann R, et al. 30 years of the mineralocorticoid receptor: nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234(1):T107–T124.
   PubMed Web of Science ®Google Scholar
• Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, et al. The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep. 2012 Dec;14(6):573–580.
   PubMed Web of Science ®Google Scholar
• Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8(1):151–188.
   PubMed Web of Science ®Google Scholar
• Kuhlmann J, Kötter V, Rietbrock N. Canrenoate disposition in dogs. Tissue distribution and elimination. Naunyn Schmiedebergs Arch Pharmacol. 1977;298(2):181–187.
   PubMed Web of Science ®Google Scholar
• Finn AM, Brown R, Sadée W. Tissue distribution of [3H]-canrenoate potassium in rabbits. J Pharm Sci. 1977 Feb;66(2):275–277.
   PubMed Web of Science ®Google Scholar
• Yamada M, Takei M, Suzuki E, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47(12):1090–1103.
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709–716.
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9(4):509–515.
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–990.
   PubMed Web of Science ®Google Scholar
• Karashima S, Yoneda T, Kometani M, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res. 2016;39(3):133–137.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Seo Y, Ishizu T, et al. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. Heart Vessels. 2019;34(2):279–289.
   PubMed Web of Science ®Google Scholar
• Ito S, Itoh H, Rakugi H, et al. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75(1):51–58.
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–2463.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–2114.
   PubMed Web of Science ®Google Scholar
• Kolkhof P, Bärfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125–T140.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kolkhof P, and Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 42 (2): 152–161. .
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204–2213.
   PubMed Web of Science ®Google Scholar
• Imai E, Chan JC, Ito S, et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011 Dec;54(12):2978–2986.
   PubMed Web of Science ®Google Scholar
• Investigators ONTARGET, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547–1559.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Agarwal R, et al. FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540–552.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Aug 28. https://doi.org/10.1056/NEJMoa2110956. Epub ahead of print.
   Google Scholar
• Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2021 Feb;25(2):120–130.
   PubMed Web of Science ®Google Scholar
• Bakris G, Pe P, Delgado B, et al. BLOCK-CKD Study Group. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: results of the BLOCK-CKD Study. Hypertension. 2021 Jul;78(1):74–81.
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Verdonschot J, Wang P, et al. HOMAGE (Heart Omics in AGEing) Consortium. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC Heart Fail. 2021 Jan 28;9(4):268–277. S2213-1779(20)30705-8
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Duarte K, Jjv M, et al. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circ Heart Fail. 2018 Jul;11(7):e004926.
   PubMed Web of Science ®Google Scholar
• Fraccarollo D, Thomas S, Scholz CJ, et al. Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. Hypertension 2019 Jan;73(1):102–111.
   PubMed Web of Science ®Google Scholar